Human erythropoietin gene therapy for patients with chronic renal failure.
نویسندگان
چکیده
Gene therapy holds a major promise. However, until now, this promise was fulfilled only in few cases, in rare genetic diseases. One very common clinical condition is anemia. Patients with anemia of chronic renal failure are treated with erythropoietin. The objective of this study was to develop a therapeutic platform for serum-secreted proteins like erythropoietin. We developed a tissue protein factory based on dermal cores (Biopump) harvested and implanted autologously. In this study, an adenovector was designed to express the human erythropoietin under the control of the cytomegalovirus (CMV) promoter. This vector transduced the harvested dermal cores ex vivo. The transduced cores were implanted, and erythropoietin and reticulocyte counts were measured. Dermal cores were harvested from 13 patients with chronic renal failure, and implantation was performed in 10. There were no significant drug-related side effects to this procedure. Erythropoietin serum levels increased significantly to therapeutic levels from day 1 after implantation reaching a peak during the first week of follow-up. The expression period was transient for up to 14 days. The rise of erythropoietin was followed by a transient significant increase in reticulocyte counts. The decrease of erythropoietin expression coincided with a significant dermal infiltrate of CD8 cytotoxic T cells. Antierythropoietin antibodies were not detected until day 90 following implantation. Implantation of dermal cores ex vivo transduced with human genes could eventually be used in the clinical setting to express therapeutic serum proteins. However, nonimmunogenic delivery system should be tested as gene vehicles.
منابع مشابه
PHARMA COKINETICS OF RECOMBINANT ERYTHROPOIETIN AND RED CELL METABOLISM IN HAEMODIALYSIS PATIENTS
The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of t...
متن کاملThe Effect of Dignity Therapy on Human Dignity in Patients with Chronic Renal Failure Undergoing Hemodialysis
Background: Chronic renal failure is a life-threatening condition; patients due to the prolonged stress are very susceptible to mental health problems. Dignity therapy is a novel therapeutic approach to the treatment of psychological problems for patients who suffer from life-threatening illnesses. Aim: This study examined the impact of dignity therapy on human dignity in patients undergoing he...
متن کاملGENE THERAPY Human erythropoietin gene therapy for patients with chronic renal failure
Gene therapy holds a major promise. However, until now, this promise was fulfilled only in few cases, in rare genetic diseases. One very common clinical condition is anemia. Patients with anemia of chronic renal failure are treated with erythropoietin. The objective of this study was to develop a therapeutic platform for serum-secreted proteins like erythropoietin. We developed a tissue protein...
متن کاملHuman Leukocyte Antigen Class I and II Variants in Yemeni Patients with Chronic Renal Failure
Background: Human leukocyte antigens (HLAs) are found to be significant genetic factors concerning the susceptibility of an individual to certain diseases. Objective: To determine the association between variants of class I (A and B) and class II (DRB1) HLA alleles and chronic renal failure (CRF), compared with healthy controls, in Yemen. Methods: A case-control study in the Urology and Nephrol...
متن کاملA Lentiviral Gene Therapy Strategy for the In Vitro Production of Feline Erythropoietin
Nonregenerative anemia due to chronic renal failure is a common problem in domestic cats. Unfortunately, administration of recombinant human erythropoietin often only improves anemia temporarily due to antibody development. In this in vitro study, feline erythropoietin cDNA was cloned from feline renal tissue and utilized in the construction of a replication-defective lentiviral vector. The nat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 106 7 شماره
صفحات -
تاریخ انتشار 2005